New treatments for hepatitis C: Life cycle lessons

Ilan S. Weisberg; Samuel H. Sigal; Ira M. Jacobson

doi:10.1007/s11901-007-0007-6

New treatments for hepatitis C: Life cycle lessons

Ilan S. Weisberg, Samuel H. Sigal, Ira M. Jacobson

Research output: Contribution to journal › Review article › peer-review

Abstract

Despite progressive advances, therapy with interferon and ribavirin has been the mainstay of treatment for chronic hepatitis C for over a decade. With the development of in vitro systems to study viral replication, there have been great advances in the understanding of hepatitis C biology, and these advances, in turn, are allowing the development of specifically targeted antiviral therapies. This review employs our current understanding of the hepatitis C replicative life cycle as a framework on which to discuss new antiviral agents under clinical investigation.

Original language	English
Pages (from-to)	75-82
Number of pages	8
Journal	Current Hepatitis Reports
Volume	6
Issue number	2
DOIs	https://doi.org/10.1007/s11901-007-0007-6
State	Published - May 2007

Access to Document

10.1007/s11901-007-0007-6

Cite this

@article{6fadf445555e4286b71651f7109defad,

title = "New treatments for hepatitis C: Life cycle lessons",

abstract = "Despite progressive advances, therapy with interferon and ribavirin has been the mainstay of treatment for chronic hepatitis C for over a decade. With the development of in vitro systems to study viral replication, there have been great advances in the understanding of hepatitis C biology, and these advances, in turn, are allowing the development of specifically targeted antiviral therapies. This review employs our current understanding of the hepatitis C replicative life cycle as a framework on which to discuss new antiviral agents under clinical investigation.",

author = "Weisberg, {Ilan S.} and Sigal, {Samuel H.} and Jacobson, {Ira M.}",

year = "2007",

month = may,

doi = "10.1007/s11901-007-0007-6",

language = "English",

volume = "6",

pages = "75--82",

journal = "Current Hepatitis Reports",

issn = "1540-3416",

publisher = "Springer Publishing Company",

number = "2",

}

TY - JOUR

T1 - New treatments for hepatitis C

T2 - Life cycle lessons

AU - Weisberg, Ilan S.

AU - Sigal, Samuel H.

AU - Jacobson, Ira M.

PY - 2007/5

Y1 - 2007/5

N2 - Despite progressive advances, therapy with interferon and ribavirin has been the mainstay of treatment for chronic hepatitis C for over a decade. With the development of in vitro systems to study viral replication, there have been great advances in the understanding of hepatitis C biology, and these advances, in turn, are allowing the development of specifically targeted antiviral therapies. This review employs our current understanding of the hepatitis C replicative life cycle as a framework on which to discuss new antiviral agents under clinical investigation.

AB - Despite progressive advances, therapy with interferon and ribavirin has been the mainstay of treatment for chronic hepatitis C for over a decade. With the development of in vitro systems to study viral replication, there have been great advances in the understanding of hepatitis C biology, and these advances, in turn, are allowing the development of specifically targeted antiviral therapies. This review employs our current understanding of the hepatitis C replicative life cycle as a framework on which to discuss new antiviral agents under clinical investigation.

UR - http://www.scopus.com/inward/record.url?scp=34249877984&partnerID=8YFLogxK

U2 - 10.1007/s11901-007-0007-6

DO - 10.1007/s11901-007-0007-6

M3 - Review article

AN - SCOPUS:34249877984

SN - 1540-3416

VL - 6

SP - 75

EP - 82

JO - Current Hepatitis Reports

JF - Current Hepatitis Reports

IS - 2

ER -

New treatments for hepatitis C: Life cycle lessons

Abstract

Access to Document

Fingerprint

Cite this